

McMillanShakespeareGroup

ASX ANNOUNCEMENT

Chair Transition

McMillan Shakespeare Limited (ASX: MMS) announces that Helen Kurincic will succeed Tim Poole as the Company's Chair at the conclusion of the upcoming Annual General Meeting on 20 October 2020. Tim will continue as a Non-Executive Director until October 2021.

Helen joined the MMS Board in September 2018. She has deep senior executive and Board experience across the healthcare and related sectors. Helen is currently the Non-Executive Chair of Integral Diagnostics Limited, and a non-executive director of Estia Health Limited, HBF Health Limited and Victorian Clinical Genetics Services. Prior to taking on several Board roles, Helen was the Chief Operating Officer and Director of Genesis Care from its earliest inception, creating and developing the first and largest radiation oncology and cardiology business across Australia.

Tim Poole said "The MMS Board is delighted that Helen will be the Company's next Chair. Helen has an extensive understanding of our business and the opportunities ahead of us. She is an outstanding director and I look forward to continuing to work closely with Helen during the next year".

Helen Kurincic said "I am honoured and excited to be taking over as the Company's next Chair. We have a range of opportunities in front of us to grow and improve our businesses. I am looking forward to working with the Board and management team to deliver on these opportunities and maximise returns to shareholders".

This announcement was authorised for release by the MMS Board.

For more information please contact:

Mark Blackburn

CFO and Company Secretary
McMillan Shakespeare Limited